您好,欢迎访问三七文档
当前位置:首页 > 医学/心理学 > 药学 > 精准医疗时代下的分子靶向抗肿瘤药物研究进展-熊佳
http//.biother.orgChinJCancerBiotherOct.2016Vol.23No.5DOI10.3872/j.issn.1007-385X.2016.05.021··Researchprogressofthemoleculartargetedanti-tumordrugsintheeraofprecisionmedicine,(,110122)No.2015021。ProjectsupportedbytheTrainingProgramofInnovationandEntrepreneurshipforCollegeStudentsinLiaoningProvinceNo.20150211994-、E-mailxiongjiacmu@163.comWEIMinjiecorrespondingauthorE-mailmjwei@hotmail.com、。、、。。、。R730.5R979.1A1007-385X201605-0708-06、、。“”、、、。、、、。。1《2014》1〗。。、。。“3R”、、、、“”“”。、、、、。3、、123。、。。2“”。。20152“”precisionmedicineinitia-tive。。2016“”·807·.、。100。2FDA12。、3。。12015-2016FDA2015.02LenvatinibEisai、、2015.02PanobinostatNovartis2015.07SonidegibNovartis2015.11OmisertinibAstrazeneca3EGFR2015.11IxazomibMillenniumPharmaceuticals2016.01SpectrilaMedacGmbH2016.04NivolumabBristol-MyersSquibb2016.04AfatinibBoehringer-Ingelheim2016.04VenetoclaxAbbVieB-2BCL-22016.04AfatinibBoehringer-Ingelheim2016.04CabozantinibExelixis2016.04VenclextaAbbVie2016.05PalbociclibPfizer、EGFR、2016.05Nivolumab&ipilimumabBMS2.1、。DNAMutThomolg1MTH1DNAMTH1。MTH1、ROSMTH14。Elf-1EtserythroblasttransformationspecificTEGFR-MEK1/2-ERK、JNK1。5Elf-1、。。-1myeloidcellleukemia-1Mcl-16miR-193bMcl-1doxorubicinMDA-MB-231。STATJAK-STATSrc。STAT3EGFR、Src、Bcl-XL、Bcl-2、Mcl-1·907·201610235VEGF、Akt。STAT3、、。7STAT3、STAT3。KRAS。8KRAS54.5%BRAF、PIK3CAHER-2。。2、Gumeitini、MeifupairuiHydrochloride、SCC-31AvelasBiosciencesAVB-620X4PharmaceuticalsX4P-001ⅠCeruleanLYNPARZAⅠTRACONTRC105ⅠSellasLifeSciencesGroupGalinpepimut-SⅠBioInventTB-403ⅠCH-5132799ⅠEpitinibⅠBasileaPharmaceuticaBAL-3833ⅠTheliatinibⅠApitolisib、、ⅠIncyteINCB-39110ⅠNolatrexedDihydrochlorideⅡNantWorksAdenovirusⅡInnocrinSeviteronelⅡImmunomedicsSacituzumabGovitecanⅡVAXIMMVXM01ⅡBayerRegorafenibⅢBoehringerIngelheimNintedanibⅢMustangBioMB-101Ⅲ2.2EGFR、BCR-Abl、ALK、VEGFR、B-RAF。·017·.96595EGFR、KRASALK。2.2.1EGFREGFR-EGFR-TKIEGFRgefitinib、erlotinib10。RNAMEG3EGFR11。12EGFR。2.2.2B-RAFB-RAF、、13B-RAF80%14。B-RAF1%~2%MEK/MAPK。15B-RAF。2.2.3anaplasticlymphomaki-naseALKcrizotinibALK57%13。10ALK16。17EGFRALKpemetexedcarboplatin。AlectinibALK18。19ceritinibALK。2.2.4VEGFRVEGFRapatinibVEGFR-220。VEGFR-221。、VEG-FR。NSCLCVEG-FRlinifanib22。2.2.5BCL-223BCL-2ABT-199AuroraAAKAMLN8237MYCN。BCL-2MCL-1Akt24。BCL-225。2.2.61(insulin-likegrowthfactor1receptor,IGF-1R)insulinreceptorsubstrateIRSIGF-1RIGF26。27IGF-1REGFR。FigitumumabIGF-1RIgG219IGF-1R。2.3、、、。28-30“”CAR-TT。1programmeddeath1PD-1PD-L1、T4cytotoxicTlymphocyte-associatedantigen-4CTLA-43132。———CTLA-4。33TNFβC35TNFβ。Yang34T———ACAT1、ACAT2。avasimibeACAT1CD8+TPD-1。2.4G35GPR160·117·201610235GPR160。RNAmiRNAs、ln-cRNAs、36。histonedeacetylaseHDAC13。isocitratedehydrogenaseIDH13。silybinCD4437。PYCR1PYCR1CRISPR38。AGR2、CADM1。。39metform-inEGFR-TKITKI。3、、。、、。、。、。1.2014J.20142014216.2.J.201639011-18.DOI10.7501/j.issn.1674-6376.2016.01.001.3.5FDAJ.20162511-6.4.MTH1J.20153191199-1201.DOI10.3969/j.issn.1001-1978.2015.09.004.5.Elf-1J.2015345851-855.DOI10.3969/j.issn.1671-6264.2015.05.039.6.miR-193bJ.20153191584-1588.DOI10.3969/j.issn.1000-4718.2015.09.009.7.STAT3J.201524273074-3078.DOI10.3969/j.issn.1008-8849.2015.27.044.8NAMSKYUNSKOHJetal.BRAFPIK3CAandHER2oncogenicalterationsaccordingtoKRASmutationstatusinad-vancedcolorectalcancerswithdistantmetastasisJ/OL.PLoSOne2016113e01518652016-07-25.http//.nc-bi.nlm.nih.gov/pmc/articles/PMC4798471/.DOI10.1371/journal.pone.0151865.9LEEBLEETLEESHetal.ClinicopathologiccharacteristicsofEGFRKRASandALKalterationsin6595lungcancersJ.Oncotarget201671723874-23884.DOI10.18632/oncotarget.8074.10.40J.201523202959-2961.DOI10.3969/j.issn.1672-4992.2015.20.23.11CHANGLWANGGJIATetal.Armoredlongnon-codingRNAMEG3targetingEGFRbasedonrecombinantMS2bacterio-phagevirus-likeparticlesagainsthepatocellularcarcinomaJ.Oncotarget201671723988-24004.DOI10.18632/onco-target.8115.12VANDPBBOONSTRAMCSLOOTERMDetal.EGFRtar-getednanobody-photosensitizerconjugatesforphotodynamictherapyinapre-clinicalmodelofheadandneckcancerJ/OL.JControlRelease201622993-1052016-07-25.http//.science-direct.com/science/article/pii/S0168365916301481.DOI10.1016/j.jconrel.2016.03.014.13ATIQRHERTZRELDADSetal.SuppressionofB-RafV600EcancersbyMAPKhyper-activationJ.Oncotarget201671418694-18704.DOI10.18632/oncotarget.7909.14.J.20153910721-722.15RAFAELCGILBERTODCJIGNACIOGBetal.BRAFmu-tationsinnon-smallcelllungcancerhasfinallyJanusopenedthedoorJ/OL.CritRevOncolHematol201610132-392016-07-25.http//.croh-online.com/article/S1040-84281630036-1/abstract.DOI10.1016/j.critrevonc.2016.02.012.16ZITOMFMORABITOAGRIDELLICetal.CrizotinibresponseinalaterelapseofALK-positivelungadenocarcinomaJ/OL.Ap-plImmunohistochemMolMorphol2016aheadofprint2016-07-25.http//journals.lww.com/appliedimmunohist/pages/articlev-·217·.iewer.aspxyear=9000&issue=00000&article=99105&type=ab-stract.DOI10.1097/PAI.0000000000000328.17FANTSONGYJLIUXL.AdenocarcinomaofthelungwithconcomitantALKfusiongeneandEGFRgenemutationacasere-portandliteraturereviewJ/OL.MolClinOncol201642203-2052016-07-25.http//.ncbi.nlm.nih.gov/pmc/ar-ticles/PMC4733966/.DOI10.3892/mco.2015.684.18TANAKAHTAIMAKMORIMOTOTetal.Dramaticre
本文标题:精准医疗时代下的分子靶向抗肿瘤药物研究进展-熊佳
链接地址:https://www.777doc.com/doc-2329302 .html